MA26660A1 - Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate. - Google Patents

Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate.

Info

Publication number
MA26660A1
MA26660A1 MA25684A MA25684A MA26660A1 MA 26660 A1 MA26660 A1 MA 26660A1 MA 25684 A MA25684 A MA 25684A MA 25684 A MA25684 A MA 25684A MA 26660 A1 MA26660 A1 MA 26660A1
Authority
MA
Morocco
Prior art keywords
propylcarbamate
phosphonooxy
aminophenyl
furanyl
tetrahydro
Prior art date
Application number
MA25684A
Other languages
English (en)
Inventor
Gordon Armitage Ian
David Searle Andrew
Singh Hardev
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26660A1 publication Critical patent/MA26660A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA25684A 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate. MA26660A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
MA26660A1 true MA26660A1 (fr) 2004-12-20

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25684A MA26660A1 (fr) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate.

Country Status (47)

Country Link
US (3) US6514953B1 (fr)
EP (2) EP1240903A3 (fr)
JP (1) JP3437553B2 (fr)
KR (1) KR100694721B1 (fr)
CN (1) CN1188422C (fr)
AP (1) AP2001002039A0 (fr)
AR (1) AR019388A1 (fr)
AT (1) ATE229964T1 (fr)
AU (1) AU766056B2 (fr)
BG (1) BG105253A (fr)
BR (1) BRPI9912156B8 (fr)
CA (1) CA2337857C (fr)
CO (1) CO5090836A1 (fr)
CZ (1) CZ300447B6 (fr)
DE (1) DE69904600T2 (fr)
DK (1) DK1098898T3 (fr)
DZ (1) DZ2845A1 (fr)
EA (1) EA003191B1 (fr)
EE (1) EE200100038A (fr)
ES (1) ES2189450T3 (fr)
GB (1) GB9815567D0 (fr)
GC (1) GC0000105A (fr)
GE (1) GEP20033030B (fr)
GT (1) GT199900111A (fr)
HR (1) HRP20010046A2 (fr)
HU (1) HU229700B1 (fr)
ID (1) ID28070A (fr)
IL (1) IL140824A (fr)
IS (1) IS5808A (fr)
JO (1) JO2114B1 (fr)
MA (1) MA26660A1 (fr)
MY (1) MY122323A (fr)
NO (1) NO329676B1 (fr)
NZ (1) NZ509291A (fr)
OA (1) OA11706A (fr)
PA (1) PA8477801A1 (fr)
PE (1) PE20000869A1 (fr)
PL (1) PL195736B1 (fr)
PT (1) PT1098898E (fr)
SK (1) SK285311B6 (fr)
SV (1) SV1999000096A (fr)
TN (1) TNSN99145A1 (fr)
TR (1) TR200100111T2 (fr)
TW (1) TWI245770B (fr)
WO (1) WO2000004033A1 (fr)
YU (1) YU3401A (fr)
ZA (1) ZA200100417B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
CA2386850C (fr) * 1999-10-06 2010-03-30 Piet Tom Bert Paul Wigerinck Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl} carbamate en tant qu'inhibiteur de protease retrovirale
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド FabI阻害剤
TW200408645A (en) * 2002-04-26 2004-06-01 Gilead Sciences Inc Non nucleoside reverse transcriptase inhibitors
PT1575951E (pt) 2002-12-06 2014-09-15 Debiopharm Int Sa Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
EP1608377B1 (fr) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Compositions comportant plusieurs agents antibiotiques, et leurs procedes de mise en oeuvre
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2004096285A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues anti-infectieux du phosphonate
EP1620109A2 (fr) 2003-04-25 2006-02-01 Gilead Sciences, Inc. Analogues de phosphonate inhibiteurs de kinase
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
PT1670448E (pt) * 2003-09-30 2008-02-11 Tibotec Pharm Ltd Sulfonamidas inibidoras de hcv
WO2005042773A1 (fr) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Procedes et compositions permettant d'identifier des composes therapeutiques
WO2005044279A1 (fr) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Conjugues phosphonate / inhibiteur de purine nucleoside phosphorylase
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
BRPI0417988A (pt) 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
EP2054422B1 (fr) 2006-07-20 2017-06-14 Debiopharm International SA Dérivés d'acrylamide en tant qu'inhibiteurs de fab i
WO2008098374A1 (fr) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Sels, promédicaments et polymorphes d'inhibiteurs de fab 1
WO2008112289A2 (fr) 2007-03-12 2008-09-18 Nektar Therapeutics Conjugués d'oligomère-inhibiteur de protéase
WO2009114151A1 (fr) * 2008-03-12 2009-09-17 Nektar Therapeutics Conjugués oligomères-acides aminés et oligomères-atazanavir
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
CN106810464B (zh) 2009-04-03 2019-01-22 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐及其制备方法
WO2010134045A1 (fr) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Fosamprenavir calcique amorphe
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
EP2440249A2 (fr) 2009-06-12 2012-04-18 Nektar Therapeutics Conjugués covalents comprenant un inhibiteurs de protéase, un oligomère non-peptidique soluble dans l'eau et une partie lipophilique
US20120208787A1 (en) 2009-06-30 2012-08-16 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
US9085592B2 (en) * 2009-09-16 2015-07-21 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
WO2011085130A1 (fr) 2010-01-07 2011-07-14 Pliva Hrvatska D.O.O. Formes solides du sel de calcium du fosamprénavir et leur procédé de synthèse
EP3351249A1 (fr) 2010-01-27 2018-07-25 VIIV Healthcare Company Thérapie antivirale
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (fr) 2010-03-19 2011-09-22 Lupin Limited Sels d'ammonium, de calcium et de tris de fosamprénavir
WO2011158259A1 (fr) 2010-06-18 2011-12-22 Matrix Laboratories Ltd Nouveau procédé pour la préparation du (1s, 2r)-3-[[(4-aminophényl)sulfonyl] (isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate de (3s)-tétrahydrofurane-3-yle et ses sels pharmaceutiquement acceptables
WO2012032389A2 (fr) 2010-09-10 2012-03-15 Lupin Limited Procédé de préparation de calcium de fosamprenavir sensiblement pur et de ses intermédiaires
EP2625162B1 (fr) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Procédés de fabrication d'acétate de phényle de l-ornithine
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (fr) 2010-12-21 2012-06-28 Lupin Limited Procédé pour la préparation de fosamprénavir calcique et d'un intermédiaire utilisé dans sa préparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (fr) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Procédé de préparation de sulfonamides utiles en tant qu'inhibiteurs de protéase rétroviraux
IN2012DE00082A (fr) 2012-01-10 2015-05-01 Council Scient Ind Res
EP2861608B8 (fr) 2012-06-19 2019-06-19 Debiopharm International SA Dérivés de type promédicament du (e)-n-méthyl-n-((3-méthylbenzofuran-2-yl) méthyl)-3-(7-oxo-5,6,7,8-tétrahydro-l,8-naphtyridin-3-yl)acrylamide
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス, インコーポレイテッド L-オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも1つと組み合わせて用いる筋肉喪失の治療および予防
DK3419628T3 (da) 2016-02-26 2021-01-11 Debiopharm Int Sa Medikament til behandling af diabetiske fodinfektioner
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
ES2944535T3 (es) 2019-02-14 2023-06-22 Debiopharm Int Sa Formulación de afabicina, método para preparar la misma
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
EP1042280A2 (fr) * 1997-12-24 2000-10-11 Vertex Pharmaceuticals Incorporated Pro-medicaments qui sont des inhibiteurs de l'aspartyl protease
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
HK1040625B (zh) * 1998-11-04 2005-04-01 法玛西雅厄普约翰美国公司 用於改善替普拉那维的药物动力学的方法
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
ES2295068T3 (es) * 1999-11-24 2008-04-16 MERCK & CO., INC. Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih.

Also Published As

Publication number Publication date
PL345620A1 (en) 2002-01-02
ATE229964T1 (de) 2003-01-15
HK1034261A1 (en) 2001-10-19
DZ2845A1 (fr) 2003-12-01
OA11706A (en) 2005-01-13
CN1324363A (zh) 2001-11-28
BG105253A (en) 2001-12-29
AR019388A1 (es) 2002-02-13
EP1240903A2 (fr) 2002-09-18
PA8477801A1 (es) 2000-05-24
EP1240903A3 (fr) 2003-02-12
HRP20010046A2 (en) 2002-02-28
CZ300447B6 (cs) 2009-05-20
PE20000869A1 (es) 2000-09-08
EP1098898A1 (fr) 2001-05-16
IS5808A (is) 2001-01-12
JP3437553B2 (ja) 2003-08-18
US20030096795A1 (en) 2003-05-22
GC0000105A (en) 2005-06-29
NO20010282L (no) 2001-03-07
PL195736B1 (pl) 2007-10-31
AP2001002039A0 (en) 2001-03-31
IL140824A (en) 2004-09-27
DE69904600D1 (de) 2003-01-30
PT1098898E (pt) 2003-04-30
EE200100038A (et) 2002-06-17
ID28070A (id) 2001-05-03
BRPI9912156B8 (pt) 2021-05-25
ZA200100417B (en) 2002-02-27
EA200100053A1 (ru) 2001-08-27
EA003191B1 (ru) 2003-02-27
CA2337857A1 (fr) 2000-01-27
EP1098898B1 (fr) 2002-12-18
MY122323A (en) 2006-04-29
DE69904600T2 (de) 2003-11-13
CN1188422C (zh) 2005-02-09
HUP0103432A3 (en) 2003-01-28
TNSN99145A1 (fr) 2005-11-10
NZ509291A (en) 2003-05-30
JO2114B1 (en) 2000-05-21
SV1999000096A (es) 2000-07-06
AU766056B2 (en) 2003-10-09
NO329676B1 (no) 2010-11-29
GT199900111A (es) 2001-01-05
ES2189450T3 (es) 2003-07-01
BR9912156A (pt) 2001-04-10
GEP20033030B (en) 2003-07-25
AU5037999A (en) 2000-02-07
TR200100111T2 (tr) 2002-02-21
CA2337857C (fr) 2011-01-25
CO5090836A1 (es) 2001-10-30
WO2000004033A1 (fr) 2000-01-27
YU3401A (sh) 2005-06-10
SK762001A3 (en) 2001-10-08
DK1098898T3 (da) 2003-04-07
KR100694721B1 (ko) 2007-03-15
HU229700B1 (en) 2014-05-28
BRPI9912156B1 (pt) 2016-07-26
US6514953B1 (en) 2003-02-04
HUP0103432A2 (hu) 2002-04-29
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
SK285311B6 (sk) 2006-10-05
NO20010282D0 (no) 2001-01-17
GB9815567D0 (en) 1998-09-16
IL140824A0 (en) 2002-02-10
CZ2001219A3 (cs) 2001-07-11
JP2003521447A (ja) 2003-07-15
TWI245770B (en) 2005-12-21

Similar Documents

Publication Publication Date Title
DE69904600D1 (de) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamat
DZ2740A1 (fr) Catalyseurs de polymésation.
DZ2737A1 (fr) Catalyseurs de polymérisation.
NO995589D0 (no) Fremgangsmåte for å bestemme senderetning, samt radiosystem
BR9700369B1 (pt) compostos de dimetil-(3-aril-but-3- enil)-amina.
ITMI982247A0 (it) Procedimento per impermeabilizzare la pelle ottenuta mediante tale procedimento
AU5818100A (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzy -2-(phosphonooxy)propylcarbamate
FR2763498B1 (fr) Endoscope, en particulier mediastinoscope
ITTO950478A0 (it) Rotore per elicotteri.
ES1047984Y (es) Corchete de ortodoncia.
HN1999000113A (es) (3s) tetrahidro - 3 - funaril (15, 2r) - 3 - [[4 - aminofenil) sulfonil)] (isobutil) amino] - 1 - bencil - 2 (fosfonooxi) propilcarbamato de calcio.
ITBO980069A0 (it) Piattaforma rotante per autoveicoli.
ES1030098Y (es) Tapa-casquillo nivelador, para somieres de ballestas.
AU8463098A (en) Process for preparing (2r,3s)-3-(substituted or unsubstituted phenyl)glycidamidecompounds by asymmetric amidation
KR950024792U (ko) 차량용 엘. 피. 지 캡(l. p. g cap)
ITBO970012A0 (it) Metodo per la formazione distrati di sigarette.
BR9611957A (pt) Di-hidrato de (2r,3s) -3- terc.- butoxicarbonilamino - 2 -hidroxi - 3 - fenilpropionato de 4,10 beta-diacetoxi - 2 - alfa-benzoiloxi-5beta, 20 - epoxi - 1 - hidroxi - 9 - oco - 19 - nor - ciclopropa[g]tax - 11eno - 13alfa - ila e processo para preparação do mesmo
ES1039039Y (es) Dardo de ventosas para juego de diana.
ES1037688Y (es) Dispositivo de ayuda para la expectoracion, no invasivo.
ES1036214Y (es) Sillita-carrito de paseo-mochila, para muñecos.
IT238487Y1 (it) Involucro esterno per piantine.
ES1040568Y (es) Instrumento de escritura.
ES1039379Y (es) Bigudi retenedor de humedad.
ITBO970443A0 (it) Tovagliolino mappa per parco giochi.
FR2766908B1 (fr) Module de ventilation, notamment pour veranda